Baird served as co-manager on this offering
AboutSyndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ-GS: SNDX) recently completed an underwritten public offering of 6,388,889 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 833,333 shares of common stock. The gross proceeds to Syndax from the offering are expected to be approximately $115.0 million.
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Syndax's lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combination with several approved PD-1/PD-(L)1 antagonists. Syndax’s pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and SNDX-5613, a highly selective inhibitor of the Menein–MLL binding interaction. Syndax Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
CONTACT US TO LEARN MORE
- May 2020
- Syndax Pharmaceuticals, Inc.
- Target Location
- North America